Published April 25, 2017
One of the most dramatic medical success stories in the past few years has been the introduction of new drugs that eradicate hepatitis C virus (HCV). But it’s a different story among HCV patients with substance use disorders.
As an editorial published online on April 25 in the Annals of Internal Medicine notes, this population typically does not have easy access to conventional health care so it is difficult to screen, diagnose and treat these individuals.
“People with substance use disorders can account for as much as 80 percent of infected individuals in developed countries, a direct result of the opioid epidemic in the U.S.,” says Andrew H. Talal, lead author of the editorial and professor in the Department of Medicine, Jacobs School of Medicine and Biomedical Sciences.
Talal, a leading expert in liver disease, is a researcher with UB’s Clinical and Translational Science Institute, funded by a National Institutes of Health Clinical and Translational Science Award. He is principal investigator with other UB faculty on a $7 million Patient-Centered Outcomes Research Institute award dedicated to developing innovative ways to treat HCV in persons with substance use disorders. The award funds efforts with these patients throughout New York State, including New York City, Buffalo, Rochester, Syracuse and the Hudson Valley.
Talal says a combination of factors all work to prevent these patients from receiving the diagnoses and care they need. Such factors range from discomfort in conventional health care settings and lack of HCV-related knowledge to fear of stigmatization that can result from an HCV diagnosis. That’s in addition to insurance barriers and physicians’ general reluctance to treat this population.
“New approaches for persons with substance use disorders are required at every step in the HCV care paradigm,” the editorial states.
The reason is that following a decade of fairly steady declines in this population, there have been recent sharp increases in HCV.
“We’re seeing infection hotspots,” Talal says, noting this is partly a result of the opioid epidemic, particularly where needle-exchange programs, for example, are not available.
Such programs are key, Talal says, citing a report issued earlier this month by the National Academies that found that people who inject drugs account for approximately 75 percent of all new HCV infections.
To better reach persons with substance use disorders, the editorial states, HCV screening and linkage to care must improve. Screening can be especially problematic because it typically requires two steps: confirmation that the person has been exposed to HCV through an antibody test, followed by additional blood work to determine if the infection is active. Currently, the second step must be conducted in a conventional laboratory, a setting these patients rarely access. Recent advances, however, are designed to assess whether all required analyses could be done onsite.
Once a diagnosis is made, getting patients connected with providers is another major hurdle.
“At best, only 20 percent of these patients connect with a provider for treatment,” Talal explains, “and often it’s far less than that.”
Talal and his colleagues at UB and other institutions and care facilities have been developing promising ways to better connect these patients with the care they need by integrating HCV screening and treatment into methadone clinics these patients already regularly attend and by reaching patients in the corrections system via telehealth techniques.
In addition to Talal, co-authors on the editorial are Jessica L. Reynolds, associate professor of medicine at UB; Dave L. Thomas, professor medicine in the Johns Hopkins School of Medicine; and Jag Khalsa, chief of the medical consequences branch in the National Institute on Drug Abuse of the NIH.